(1,2) Platelet counts, platelet morphology, prothrombin and activated thromboplastin
times are all within normal ranges in patients with Glanzmann's thrombasthenia and diagnosis is only by platelet aggregation studies.
Local fibrinolytic therapy with 10 mg of alteplase (recombinant tissue plasminogen activator-rtPA) was initiated, followed by systemic sodium heparin (250 IU/Kg) to achieve a target activated thromboplastin
time between 1.5-fold and 2.0-fold over the normal range.
This can invariably leads to a prolonged partially activated thromboplastin
time test, the production of a hepic anticoagulant, anticardiolipin antibodies and several abnormalities.17 This could be responsible for the increase in PT and PTTK observed in this study in the control subjects and much more higher values observed in the test subjects.
A randomized trial comparing activated thromboplastin
time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin.
Thromboembolism in patients with abnormally short activated thromboplastin